

Biophytis announces the issuance of a €3 million tranche of ORNANEBSA

Paris, 7th July, 2017, 18:00 – BIOPHYTIS (Euronext Growth Paris: ALBPS), a biotechnology company specialized in the development of drug candidates to treat ageing diseases, announces the issuance of 300 Bonds Redeemable in Cash or New or Existing Shares (ORNANE), for a total amount of €3 million, simultaneously with the issuance of 205,959 share subscription warrants.

On 3rd April 2017 Biophytis issued 1,500 warrants to issue Notes Redeemable in Cash or New or Existing Shares (ORNANE), at a nominal value of €10,000 each, combined with Share Subscription Warrants (BSA). The note warrants were fully subscribed by Bracknor Fund. The company issued a first tranche with a value of €3 million on 15th May 2017.

The Company will keep the shareholders informed of the exercise of the ORNANEBSA warrants and the subsequent conversions, through a reporting schedule of the note warrants, the ORNANE, the share subscription warrants, and the number of shares in circulation, which will be available on the Company website.

Main characteristics of the ORNANE issued

The 300 ORNANE issued will have a 12-month maturity from issuance. The holder may request at any time their redemption during their maturity period, and on this occasion the Company will be able to redeem the ORNANE in cash. The ORNANE will not be subject to a request for admission to trading on the Euronext Growth market.

Main characteristics of the warrants issued

The 205,959 warrants issued may be exercised for a period of 5 years as of their date of issue, at the exercise price of €3.64. Each warrant will give its holder the right to subscribe one (1) new Biophytis share. The warrants will not be subject to a request for admission to trading on the Euronext Growth market.

Number of securities and dilution

Based on the 8,919,017 outstanding shares, and based on an issuance, or the conversion, or exercise, 7th July 2017, i.e., a lowest volume weighted average price over the 10 trading days preceding the concerned date equal to €3.17.

Impact on a shareholder's 1% stake in the Company's capital prior to the operation	Non-diluted basis	Diluted basis
Before issuance of the ORNANEBSA	1.00	0.90
After issuance of 1,027,397 new shares issued from the conversion of this ORNANE tranche	0.90	0.80
After issuance of 1,027,397 new shares issued from the conversion of the second ORNANE tranche and the issuance of 205,959 shares issued from the exercise of the second tranche of warrants	0.88	0.79

About BIOPHYTIS:

Biophytis SA (www.biophytis.com), founded in 2006, develops drug candidates targeting diseases of aging. Using its technology and know-how, Biophytis has begun clinical development of innovative therapeutics to restore the muscular and visual functions in diseases with significant unmet medical need. Specifically, the company is advancing two lead products into mid-stage clinical testing this year: Sarconeos (BIO101) to treat sarcopenic obesity and Macuneos (BIO201) to treat dry age-related macular degeneration (AMD). The company was founded in partnership with researchers at the UPMC (Pierre and Marie Curie University) and also collaborates with scientists at the Institute of Myology, and the Vision Institute.

BIOPHYTIS is listed on the Euronext Growth market of Euronext Paris (ALBPS; ISIN: FR0012816825).

For more information: <http://www.biophytis.com>

 Follow us on Twitter @biophytis

BIOPHYTIS is eligible for the SMEs scheme



Disclaimer

This press release contains certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially

from those anticipated. For a discussion of risks and uncertainties which could cause the Company's actual results, financial condition, performance or achievements to differ from those contained in the forward looking statements, please refer to the Risk Factors (“Facteurs de Risque”) section of the Listing Prospectus upon the admission of Company’s shares for trading on the regulated market Euronext Growth of Euronext Paris filed with the AMF, which is available on the AMF website (www.amf-france.org) or on BIOPHYTIS’ website (www.biophytis.com).

This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in BIOPHYTIS in any country. Items in this press release may contain forward-looking statements involving risks and uncertainties. The Company’s actual results could differ substantially from those anticipated in these statements owing to various risk factors which are described in the Company’s prospectus. This press release has been prepared in 5 both French and English. In the event of any differences between the two texts, the French language version shall supersede.

BIOPHYTIS

Stanislas VEILLET

CEO

contact@biophytis.com

Tel : +33 (0) 1 41 83 66 00

Citigate Dewe Rogerson

International media & Investors

Laurence BAULT/Antoine DENRY

Laurence.bault@citigate.fr/antoine.denry@citigate.fr

Tel : +33 (0)1 53 32 84 78

Mob : +33(0)6 64 12 53 61

LifeSci Advisors

Chris MAGGOS

Managing Director, Europe

chris@lifesciadvisors.com

Tel : +41 79 367 6254